Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Acta Oncologica

Volumn 49, Issue 1, 2010, Pages 113-116

  Desar, Ingrid M E ^a   Bovenschen, H Jorn ^a   Timmer Bonte, Anja J N H ^a   Cantarini, Mireille V ^b   Van Der Graaf, Winette T A ^a   Van Rossum, Michelle M ^a   Van Herpen, Carla M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CETOMACROGOL; CHLORHEXIDINE; DACARBAZINE; DESOXIMETASONE; ERYTHROMYCIN; MINOCYCLINE; POVIDONE IODINE; SALICYLIC ACID; SILVER NITRATE; STEROID;

ACNE; ADULT; ALOPECIA; CASE REPORT; CHOROID MELANOMA; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLICULITIS; HAIR DISCOLORATION; HAND FOOT SYNDROME; HUMAN; LETTER; LIVER METASTASIS; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PAPULE; PARONYCHIA; PRIORITY JOURNAL; PSORIASIS; PUNCH BIOPSY; PUSTULE; SKIN NODULE; SKIN PAIN; SKIN PRURITUS; SKIN TOXICITY; SOLID TUMOR; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSIS;

EID: 76649090958     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903104152     Document Type: Letter

References (15)

1. Beeram M, Patnaik A, Rowinsky EK. Raf: A strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-90.
2. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-6.
3. Dummer R, Robert C, Chapman PB, Sosman JA, Middleton M, Bastholt L, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multi-center, phase II study. J Clin Oncol 2008;26:(Abstract)9033.
4. Agarwal R, Banergi U, Camidge CR, Brown KH, Cantarini CV, Morris C, et al. The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer. J Clin Oncol 2008;26: (Abstract)3535.
5. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33.
6. Sarker D, Banergi U, Agarwal R. Relative oral bioavailability of the hydrogen sulphate (Hyd-sulfate) capsule and free-base suspension formulations of AZD6244 (ARRY-142886): A Phase I trial in patients with advanced cancer. Ann Oncol 2008;19:/viii153-viii165.
7. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-12.
8. Schad K, Baumann Conzett K, Zipser MC et al. MEK kinase inhibition (mitogen-activated protein/extracellular signal-regulated kinase kinase) by AZD6244 (ARRY-142886) results in severe disturbance of epidermal homeostasis with acute inflammation and chronic maladaptation. 2008 (submitted).
9. Ben Bassat H, Klein BY. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 2000;6:933-42.
10. Wierzbicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 2006;155:213.
11. Varani J, Kang S, Stoll S, Elder JT. Human psoriatic skin in organ culture: Comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology 1998;66:253-9.
12. Powell TJ, Ben Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, et al. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 1999;141:802-10.
13. Autier J, Escudier B, Wechsler, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-92.
14. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7:48-54.
15. Sapadin AN, Fleishmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermtol 2006;54:258-65.